Metabolic Endocrinology Type I Diabetes

Table of Contents

RECENT HIGHLIGHTS AND CHANGES
--Recent Highlights and Changes
UPCOMING PATENT EXPIRES BY THERAPY AREA
Type I Diabetes Pipeline Overview
--% of Projects (By Phase of Development)
--No. of Projects by Phase of Development
--Marketed Products Vs. Pipeline Products
Company Overview - Pipeline Projects
--Company Overview - Pipeline Projects

--Top Companies in late stage Type I Diabetes Projects
--AutoImmune Inc
--AmCyte Inc.
--BTG plc
--Bayhill Therapeutics, Inc.
--DeveloGen AG
--Chong Kun Dang Pharmaceutical Corp.
--Pharm)
--Diamyd Medical AB
--Diabetology Ltd
--Generex Biotechnology Corporation
--Eli Lilly & Co
--GlaxoSmithKline plc
--Genzyme Corporation
--Living Cell Technologies Ltd
--Insmed Incorporated
--Novocell, Inc.
--MacroGenics Inc.
--Procter & Gamble Company
--Osiris Therapeutics Inc
--Tolerx, Inc.
--Protein Sciences Corporation

--Top Companies in early stage Type I Diabetes Projects
--Alba Therapeutics Corporation
--AdPharma, Inc.
--Eli Lilly & Co
--DiaKine Therapeutics, Inc.
--Geron Corporation
--FIT Biotech Oyj Plc.
--Living Cell Technologies Ltd
--Lipoxen
--MultiCell Technologies Inc
--MicroIslet, Inc.
--Oramed Pharmaceuticals Inc
--Novocell, Inc.
--ReNeuron Group plc
--Plantigen Inc.
--Sernova Corp
--erly Pheromone Sciences Corp)
--Schering-Plough Corp
--VGX Pharmaceuticals, Inc
--Target-In Ltd.

Full Pipeline View
--Pre Clinical Pipeline View
--Phase I Pipeline View
--Phase II Pipeline View
--Phase III Pipeline View
--On the Market Pipeline View
--Discovery/Development Pipeline View